Allergy Immunotherapy Market By Treatment Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy), By Allergy Type (Allergic Rhinitis, Allergic Asthma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Allergy Immunotherapy Market was valued at USD 2.5 billion in 2023 and will surpass USD 4.9 billion by 2030; growing at a CAGR of 10.1% during 2024 - 2030.

The global allergy immunotherapy market is poised for substantial growth, driven by the increasing prevalence of allergic conditions such as allergic rhinitis and allergic asthma. As the demand for effective, long-term treatment options rises, immunotherapy has gained prominence due to its ability to address the root cause of allergies, providing relief for patients who do not find sufficient relief from traditional allergy medications. This market encompasses both subcutaneous (SCIT) and sublingual (SLIT) forms of immunotherapy, with notable growth across different allergic conditions and distribution channels. Factors such as the growing awareness of immunotherapy benefits, increasing patient demand for personalized treatments, and advancements in drug formulations and delivery methods are expected to fuel the market's growth from 2024 to 2030.

Among the various subsegments, sublingual immunotherapy (SLIT) is rapidly gaining traction due to its convenience and non-invasive nature. This treatment option, which includes both tablets and drops, offers patients an alternative to the more traditional subcutaneous injections. The shift toward SLIT is being driven by factors such as ease of administration, reduced risk of side effects, and the growing availability of effective SLIT-based treatments for seasonal and perennial allergies. SLIT tablets, in particular, are emerging as the preferred option in key markets due to their ability to be self-administered at home, providing a high degree of flexibility for patients. This form of immunotherapy is expected to maintain strong growth due to these advantages, further enhancing its adoption across global markets.

Sublingual Immunotherapy Is Fastest Growing Owing to Patient Convenience

Sublingual immunotherapy (SLIT), particularly in the form of tablets, is emerging as the fastest growing subsegment within the allergy immunotherapy market. SLIT has gained significant attention due to its patient-friendly nature, as it offers a convenient alternative to traditional allergy shots. Unlike subcutaneous immunotherapy, which requires patients to visit clinics for regular injections, SLIT can be self-administered at home, making it highly desirable for patients who prefer a more convenient, less invasive option. Furthermore, SLIT has been shown to be highly effective in treating a range of allergies, including grass pollen, ragweed, and dust mites, which further boosts its appeal.

The global market for SLIT is being bolstered by increasing regulatory approvals for new SLIT products, particularly in the tablet form. Regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have approved several SLIT tablet products in recent years, which has opened up new avenues for market growth. The availability of these FDA- and EMA-approved treatments has increased clinician and patient confidence in SLIT, fueling its adoption. In addition, SLIT is expected to capture a larger share of the market as awareness grows among patients and healthcare providers about the benefits of non-invasive allergy treatments.

Allergic Rhinitis Is Largest Segment Due to Prevalence

Allergic rhinitis holds the largest share in the allergy immunotherapy market, driven by its high prevalence worldwide. This condition, often referred to as hay fever, is characterized by symptoms such as sneezing, nasal congestion, runny nose, and itchy eyes, which affect millions of people globally. The global burden of allergic rhinitis is significant, with a considerable portion of the population suffering from seasonal or perennial forms of the condition. As a result, treatments targeting allergic rhinitis, including allergy immunotherapy, are in high demand. Immunotherapy is seen as a long-term solution for patients with moderate to severe symptoms, offering potential relief after a course of treatment.

Immunotherapy for allergic rhinitis has proven to be effective in not only alleviating symptoms but also in reducing the need for long-term use of pharmacological treatments such as antihistamines and nasal corticosteroids. The largest market share for allergy immunotherapy is thus driven by the widespread use of SCIT and SLIT to treat allergic rhinitis. With the increasing prevalence of allergies, especially in urban populations, the demand for more effective and durable treatment options like immunotherapy is expected to continue to rise, making allergic rhinitis the dominant segment in this market.

Hospital Pharmacy Dominates Due to Accessibility

The hospital pharmacy segment leads the allergy immunotherapy market, driven by the high volume of patients seeking specialized allergy treatments in medical settings. Hospitals are key locations for delivering allergy immunotherapy, especially subcutaneous immunotherapy (SCIT), which requires administration by trained healthcare professionals. These pharmacies are equipped to provide not only the medications but also the necessary infrastructure to monitor patients for any immediate allergic reactions that may occur following treatment. As a result, hospital pharmacies are typically the primary distribution channel for SCIT, particularly in the early phases of treatment when patients require frequent visits for injections.

While retail and online pharmacies are growing, especially for the distribution of SLIT tablets, hospital pharmacies remain the most significant channel due to the specialized nature of allergy immunotherapy treatments. Many patients opting for SCIT rely on the expertise and support offered in hospital settings. Moreover, hospital pharmacies offer patients access to comprehensive care, including consultation with allergists and immunologists, ensuring that treatment plans are tailored to individual needs. This established trust in medical institutions is expected to keep hospital pharmacies as the dominant distribution channel for the foreseeable future.

North America Leads Due to High Healthcare Adoption

North America is the largest regional market for allergy immunotherapy, primarily driven by the advanced healthcare infrastructure, high prevalence of allergic diseases, and the adoption of innovative treatment options. The U.S., in particular, accounts for a significant share of the market, due to the well-established healthcare system and the widespread availability of allergy specialists who offer immunotherapy as a treatment option. Additionally, regulatory bodies such as the FDA have facilitated the approval of several allergy immunotherapy products, further encouraging adoption. The availability of both SCIT and SLIT options in North America is a key factor contributing to the region's dominant position in the market.

The growing awareness among patients about the effectiveness of allergy immunotherapy, combined with increasing healthcare expenditures and insurance coverage for these treatments, has made North America a major hub for immunotherapy adoption. The region is also seeing a shift towards at-home treatments like SLIT tablets, further boosting the market's growth. As the demand for allergy immunotherapy continues to rise, North America is expected to maintain its leadership in the global market.

Leading Companies and Competitive Landscape

The global allergy immunotherapy market is highly competitive, with several key players dominating the space. Companies such as Stallergenes Greer, ALK-Abelló, Merck & Co., Regeneron Pharmaceuticals, and Hycor Biomedical are at the forefront of developing and marketing allergy immunotherapy products. These companies invest heavily in research and development to bring new and improved treatments to market, with a focus on both sublingual and subcutaneous immunotherapy options.

The competitive landscape is characterized by ongoing innovations in drug formulations, including the development of new SLIT tablets and the refinement of SCIT therapies. Partnerships and acquisitions also play a significant role, as companies seek to expand their portfolios and enhance their product offerings. In addition, regulatory approvals and collaborations with healthcare providers are critical for gaining market share. The market is expected to remain dynamic, with competition centered around product efficacy, patient convenience, and cost-effectiveness. As more treatment options become available, companies will likely focus on patient-centered approaches to gain a competitive edge in this rapidly growing market.

Recent Developments: -

• Stallergenes Greer – Launched a new line of sublingual immunotherapy tablets targeting seasonal allergies, expanding its treatment options for allergic rhinitis.
• Regeneron Pharmaceuticals – Acquired a key immunotherapy technology company to enhance its portfolio in allergy treatments, particularly for allergic asthma.
• ALK-Abelló – Received regulatory approval in Europe for a new sublingual immunotherapy tablet for grass pollen allergies, marking a major milestone in expanding its allergy treatment options.
• Merck & Co. – Announced a strategic partnership with a biotech firm to co-develop next-generation allergy immunotherapy products targeting both rhinitis and asthma.
• Hycor Biomedical – Launched a new diagnostic device for personalized allergy immunotherapy treatment, enabling more tailored approaches to patient care.

List of Leading Companies:

• ASIT Biotech

Report Scope: